Tetra Pharm Technologies TPT0701: Novel Appetite Suppressant
Drug Updates

Tetra Pharm Technologies Advances CB1 Antagonist TPT0701 for Appetite Suppression into Preclinical Testing

Following the successful filing of the Intellectual Property (IP) for its applied platform technology targeting the endocannabinoid system (ECS), Tetra Pharm Technologies is moving forward with its appetite suppression supplement, TPT0701. Modulation of the endocannabinoid system has long been recognized as a promising way to regulate appetite. Through intensive research and development, Tetra Pharm Technologies […]

Argenx VYVDURA: Japan Approval for Myasthenia Gravis Treatment
Drug Updates

Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that argenx received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) injection co-formulated with Halozyme’s ENHANZE® drug delivery technology for subcutaneous (SC) use for the treatment of adult patients with generalized myasthenia gravis (gMG), who do not have sufficient response to steroids or non-steroidal […]

Drug Updates

Drug delivery innovation across Europe improves for third consecutive year ahead of Pharmapack Europe

Paris:  Ahead of Pharmapack Europe 2021 (Paris Expo, Porte de Versailles, 13-14 October) – the returning European event dedicated to drug packaging and delivery – there has been a huge swathe of innovation across the industry, with more than 53 FDA approvals in 2020 and 26 approvals in 2021. In fact, since February 2020 when the event was held last, the Pharmapack […]